FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2187941371> ?p ?o ?g. }

• W2187941371 abstract "Glioblastoma are the most common primary brain tumors in adults with a median survival of one year even with multimodal therapy including surgical resection, radiotherapy, and chemotherapy. Important hallmarks of these tumors are vascular proliferation, diffuse invasion of tumor cells into the surrounding brain tissue and effective suppression of the immune system. The efficacy of resection and current radiochemotherapy treatment regimens are therefore extremely limited. Both the genesis and development as well as the progression of malignant gliomas are highly dependent on angiogenic processes, the formation of new blood vessels from pre-existing vessels. Current treatment strategies tested in clinical trials targeting tumor angiogenesis have so far not been proven to increase survival of the patients. In addition to the insufficiency of clinical trials done, this has been attributed to several potent evasion strategies occurring at disease progression and recurrence, including increasing infiltrative tumor growth, commonly referred to as ‘evasive resistance’. These invasive growth patterns occur in addition as responses to radiotherapy and essentially trigger disease progression and have a strong influence on patients’ survival. Parts of the work presented here address the challenge of targeting the evasive resistance in glioblastoma in order to develop novel treatment strategies for a clinical application which combine anti-angiogenic with radio-enhanced anti-invasive modalities. Several strategies, focusing on different molecular targets, were undertaken: (1) Activation of the PI3K/AKT/mTOR signaling pathway is relatively common in human glioblastoma and is associated with poor survival. A clinically relevant radiation-enhanced inhibition of this pathway, using the mTOR inhibitor CCI 779, resulted in the dual control of angiogenesis and excessive invasiveness. This is mediated by a combined disrupture of the VEGF/VEGFR-2 angiogenic signaling axis on glioblastoma as well as on endothelial cells and suppression of RGS4, which was identified to be a key driver of glioblastoma invasiveness. (2) Following compelling evidence, proving that invasiveness is mediated in apoptosis-resistant glioblastoma in part by the CD95 death receptor system, antagonism of the receptor-ligand interaction was accomplished by the CD95-ligand inhibitor APG101. Clinically relevant administration of this novel compound resulted in inhibition of invasion-driving effector molecules, reduced unwanted radiotherapy-induced invasiveness, and prolonged survival of glioma-bearing mice. In addition to increased angiogenesis and invasive growth, glioblastoma effectively inhibit antitumor immune responses. Impaired recognition and attack by the immune system is effectively achieved by creating an immunosuppressive microenvironment through expression and secretion of several factors. In order to identify potential immunotherapy related targets, the costimulatory molecule B7H3 was investigated for its role in glioblastoma immunobiology. Expression correlates with grades of glioma malignancy and is associated with poor patients’ survival. Cell-bound and secreted B7H3 was identified to suppress tumor attacks by the immune system as well as to mediate invasiveness of glioblastoma cells. From the findings presented in this thesis, several therapeutic options emerge for targeting unwanted adaptive evasive escape and immunosuppression and should be considered for further clinical investigation in glioblastoma therapy." @default.
• W2187941371 created "2016-06-24" @default.
• W2187941371 creator A5056275665 @default.
• W2187941371 date "2011-01-01" @default.
• W2187941371 modified "2023-09-28" @default.
• W2187941371 title "RGS4, CD95L and B7H3: Targeting evasive resistance and the immune privilege of glioblastoma" @default.
• W2187941371 cites W114449204 @default.
• W2187941371 cites W1276188711 @default.
• W2187941371 cites W1537447319 @default.
• W2187941371 cites W1544100339 @default.
• W2187941371 cites W1560814177 @default.
• W2187941371 cites W1573363574 @default.
• W2187941371 cites W1575973365 @default.
• W2187941371 cites W1593019308 @default.
• W2187941371 cites W1750751906 @default.
• W2187941371 cites W1793932148 @default.
• W2187941371 cites W1908619062 @default.
• W2187941371 cites W1911965864 @default.
• W2187941371 cites W1931474344 @default.
• W2187941371 cites W1967894078 @default.
• W2187941371 cites W1968225435 @default.
• W2187941371 cites W1968797465 @default.
• W2187941371 cites W197014098 @default.
• W2187941371 cites W1970174108 @default.
• W2187941371 cites W1975519085 @default.
• W2187941371 cites W1977786378 @default.
• W2187941371 cites W1977999028 @default.
• W2187941371 cites W1978041336 @default.
• W2187941371 cites W1980275866 @default.
• W2187941371 cites W1981153972 @default.
• W2187941371 cites W1981289962 @default.
• W2187941371 cites W1981404696 @default.
• W2187941371 cites W1985890505 @default.
• W2187941371 cites W1987452783 @default.
• W2187941371 cites W1988609792 @default.
• W2187941371 cites W1988692970 @default.
• W2187941371 cites W1989817592 @default.
• W2187941371 cites W1994001783 @default.
• W2187941371 cites W1994567037 @default.
• W2187941371 cites W1996679013 @default.
• W2187941371 cites W1997773537 @default.
• W2187941371 cites W1999211774 @default.
• W2187941371 cites W1999601388 @default.
• W2187941371 cites W1999641808 @default.
• W2187941371 cites W1999778470 @default.
• W2187941371 cites W2002659820 @default.
• W2187941371 cites W2003217493 @default.
• W2187941371 cites W2003736915 @default.
• W2187941371 cites W2004645606 @default.
• W2187941371 cites W2005055996 @default.
• W2187941371 cites W2005770035 @default.
• W2187941371 cites W2005823843 @default.
• W2187941371 cites W2006559495 @default.
• W2187941371 cites W2007332721 @default.
• W2187941371 cites W2007729936 @default.
• W2187941371 cites W2008825756 @default.
• W2187941371 cites W2011209372 @default.
• W2187941371 cites W2013647024 @default.
• W2187941371 cites W2014830625 @default.
• W2187941371 cites W2015370039 @default.
• W2187941371 cites W2015793629 @default.
• W2187941371 cites W2017322644 @default.
• W2187941371 cites W2017331741 @default.
• W2187941371 cites W2017451768 @default.
• W2187941371 cites W2018016372 @default.
• W2187941371 cites W2023012828 @default.
• W2187941371 cites W2023234343 @default.
• W2187941371 cites W2024206845 @default.
• W2187941371 cites W2024405236 @default.
• W2187941371 cites W2025201985 @default.
• W2187941371 cites W2025504334 @default.
• W2187941371 cites W2026351725 @default.
• W2187941371 cites W2026842413 @default.
• W2187941371 cites W2028437938 @default.
• W2187941371 cites W2029470215 @default.
• W2187941371 cites W2029763637 @default.
• W2187941371 cites W2031968704 @default.
• W2187941371 cites W2032560191 @default.
• W2187941371 cites W2033093399 @default.
• W2187941371 cites W2039233803 @default.
• W2187941371 cites W2039531647 @default.
• W2187941371 cites W2039856166 @default.
• W2187941371 cites W2040931015 @default.
• W2187941371 cites W2052644931 @default.
• W2187941371 cites W2052824223 @default.
• W2187941371 cites W2053318593 @default.
• W2187941371 cites W2054455334 @default.
• W2187941371 cites W2054717287 @default.
• W2187941371 cites W2057106513 @default.
• W2187941371 cites W2057919501 @default.
• W2187941371 cites W2060157525 @default.
• W2187941371 cites W2061395079 @default.
• W2187941371 cites W2064360454 @default.
• W2187941371 cites W2064569183 @default.
• W2187941371 cites W2065887259 @default.
• W2187941371 cites W2068512864 @default.
• W2187941371 cites W2070412580 @default.
• W2187941371 cites W2070705072 @default.
• W2187941371 cites W2073272563 @default.
• W2187941371 cites W2074152898 @default.

• next